Report : Europe Sepsis Diagnostics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Instruments, Reagents and Assays, Blood Culture Media, and Software), Technology [Molecular Diagnostics (Polymerase Chain Reaction, Peptide Nucleic Acid-Fluorescent in Situ Hybridization, Syndromic Panel-Based Testing, and Microarrays), Flow Cytometry, Microfluidics, Immunoassay, Biomarkers, and Microbiology], Method (Automated Diagnostics and Conventional Diagnostics), Test Type (Point-of-Care Tests and Laboratory Tests), Pathogen (Bacterial Sepsis, Fungal Sepsis, and Others), and End User (Hospitals, Pathology and Reference Laboratories, and Others)
At 9.3% CAGR, the Europe Sepsis Diagnostics Market is speculated to be worth US$ 360.55 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the Europe sepsis diagnostics market was valued at US$ 193.12 million in 2021 and is expected to reach US$ 360.55 million by 2028, registering an annual growth rate of 9.3% from 2021 to 2028. High incidence of sepsis due to increasing nosocomial infections and increase in demand for rapid diagnostic tests leading to increasing product launches are the critical factors attributed to the market expansion.
Sepsis has a high mortality and morbidity rate. According to an article published by the National Center for Biotechnology Information (NCBI) in February 2019, it was estimated that the mortality rate of sepsis was 25–30%. Additionally, in September 2020, World Health Organization (WHO) estimated that each year almost 50% cases of sepsis occur among children, resulting in 2.9 million deaths. Most deaths can be prevented through early diagnosis and appropriate clinical management. These deaths are often a consequence of diarrheal diseases or lower respiratory infections. Thus, the high incidence rate of sepsis is expected to boost the demand for sepsis diagnostic products, thereby supporting the sepsis diagnostics market growth during the forecast period. This is expected to drive the market during the forecast period.
On the contrary, absence of skilled professionals hurdles the growth of Europe sepsis diagnostics market.
Based on product, the Europe sepsis diagnostics market is divided into instruments, reagents and assays, blood culture media, and software. The blood culture media segment held 43.5% market share in 2021, amassing US$ 84.04 million. It is projected to garner US$ 155.75 million by 2028 to expand at 9.2% CAGR during 2021–2028.
Based on technology, the Europe sepsis diagnostics market is categorized into molecular diagnostics, flow cytometry, microfluidics, immunoassay, biomarkers, and microbiology. The microbiology segment held 44.6% market share in 2021, amassing US$ 86.15 million. It is projected to garner US$ 158.17 million by 2028 to expand at 9.1% CAGR during 2021–2028. Further molecular diagnostics flow cytometry segment is further categorized into polymerase chain reaction, peptide nucleic acid-fluorescent in situ hybridization, syndromic panel-based testing, microarrays.
Based on Method, the Europe sepsis diagnostics market is categorized into automated diagnostics and conventional diagnostics. The conventional diagnostics segment held 66.5% market share in 2021, amassing US$ 128.44 million. It is projected to garner US$ 237.33 million by 2028 to expand at 9.2% CAGR during 2021–2028
Based on test type, the Europe sepsis diagnostics market is divided into point-of-care tests and laboratory tests. The laboratory tests segment held 84.4% market share in 2021, amassing US$ 162.98 million. It is projected to garner US$ 303.03 million by 2028 to expand at 9.3% CAGR during 2021–2028
Based on pathogen, the Europe sepsis diagnostics market is divided into bacterial sepsis, fungal sepsis, and others. The bacterial sepsis segment held 79.7% market share in 2021, amassing US$ 153.95 million. It is projected to garner US$ 291.60 million by 2028 to expand at 9.6% CAGR during 2021–2028
Based on end user, the Europe sepsis diagnostics market is divided into hospitals, pathology and reference laboratories, and others. The hospitals segment held 47.6% market share in 2021, amassing US$ 91.89 million. It is projected to garner US$ 172.82 million by 2028 to expand at 9.4% CAGR during 2021–2028
Based on country, the Europe sepsis diagnostics market has been categorised into the Germany, UK, France, Italy, Spain, and Rest of Europe. Our regional analysis states that Germany captured 27.7% market share in 2021. It was assessed at US$ 53.52 million in 2021 and is likely to hit US$ 100.69 million by 2028, exhibiting a CAGR of 9.5% during the forecast period.
Key players dominating the Europe sepsis diagnostics market are Abbott; F. HOFFMANN-LA ROCHE LTD.; Immunexpress Inc.; BD; Danaher (Beckman Coulter); Luminex Corporation; THERMO FISHER SCIENTIFIC INC.; bioMerieux SA; Axis-Shield Diagnostics Ltd; and T2 Biosystems, Inc. among others.
- In Feb 2022, Abbott recalls infant formula powders tied to infections.
- In Jan 2020, Inotrem secures strategic licensing agreement for a companion diagnostics test in septic shock.
Contact Person: Sameer Joshi
Email Id: firstname.lastname@example.org